Lifecore Biomedical to Report Financial Results for First Quarter of Fiscal 2025 Prior to Market Open on October 4, 2024

LFCR 10.03.2024

SERA-AI Powered Highlights
Full Press ReleaseSEC FilingsOur LFCR Tweets

About Gravity Analytica

Recent News

  • 01.17.2025 - Lifecore Biomedical Announces Special Stockholder Meeting
  • 01.07.2025 - Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million
  • 01.06.2025 - Lifecore Biomedical to Participate at 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.21.2025 - PRE 14A Other preliminary proxy statements
  • 01.17.2025 - 8-K Current report
  • 01.17.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Lifecore Biomedical to Report Financial Results for First Quarter of Fiscal 2025 Prior to Market Open on October 4, 2024

October 03, 2024
PDF Version

CHASKA, Minn.,Oct. 03, 2024(GLOBE NEWSWIRE) --Lifecore Biomedical, Inc.(NASDAQ:LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the first quarter of fiscal year 2025 onFriday, October 4, 2024, prior to market open and will host a webcast at8:30 a.m. Eastern Time. Members of Lifecore’s senior management team will discuss financial results for the first quarter and review recent corporate developments.

To listen to the live webcast, or access the archived webcast, please visit the Investor Events & Presentations page of Lifecore’s website at:https://ir.lifecore.com/events-presentations.

About Lifecore Biomedical

Lifecore Biomedical, Inc.(Nasdaq:LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website atwww.lifecore.com.

Lifecore Biomedical, Inc. Contact Information:Vida Strategic PartnersStephanie Diaz (Investors)415-675-7401sdiaz@vidasp.comTim Brons (Media)415-675-7402tbrons@vidasp.com

Primary Logo

Source: Lifecore Biomedical, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com